Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci

Paloma Anguita-Alonso, Mark S. Rouse, Kerryl E. Piper, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The activity of garenoxacin was compared to that of levofloxacin or penicillin in a rabbit model of Streptococcus mitis group (penicillin MIC, 0.125 μg/ml) and Streptococcus sanguinis group (penicillin MIC, 0.25 μg/ml) endocarditis. Garenoxacin and levofloxacin had MICs of 0.125 and 0.5 μg/ml, respectively, for both study isolates. Rabbits with catheter-induced aortic valve endocarditis were given no treatment, penicillin at 1.2 × 10 6 IU/8 h intramuscularly, garenoxacin at 20 mg/kg of body weight/12 h intravenously, or levofloxacin at 40 mg/kg/12 h intravenously. For both isolates tested, garenoxacin area under the curve (AUC)/MIC and maximum concentration of drug in serum (Cmax)/MIC ratios were 368 and 91, respectively. Rabbits were sacrificed after 3 days of treatment; cardiac valve vegetations were aseptically removed and quantitatively cultured. For S. mitis group experimental endocarditis, all studied antimicrobial agents were more active than no treatment (P < 0.001), whereas for S. sanguinis group endocarditis, no studied antimicrobial agents were more active than no treatment. We conclude that AUC/MIC and Cmax/MIC ratios may not predict activity of some quinolones in experimental viridans group endocarditis and that garenoxacin and levofloxacin may not be ideal choices for serious infections caused by some quinolone-susceptible viridans group streptococci.

Original languageEnglish (US)
Pages (from-to)1263-1267
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume50
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Viridans Streptococci
Endocarditis
Levofloxacin
Penicillins
Streptococcus mitis
Quinolones
Anti-Infective Agents
Rabbits
Area Under Curve
Heart Valves
Streptococcus
Aortic Valve
Catheters
Body Weight
garenoxacin
Infection
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci. / Anguita-Alonso, Paloma; Rouse, Mark S.; Piper, Kerryl E.; Steckelberg, James M.; Patel, Robin.

In: Antimicrobial Agents and Chemotherapy, Vol. 50, No. 4, 04.2006, p. 1263-1267.

Research output: Contribution to journalArticle

Anguita-Alonso, Paloma ; Rouse, Mark S. ; Piper, Kerryl E. ; Steckelberg, James M. ; Patel, Robin. / Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci. In: Antimicrobial Agents and Chemotherapy. 2006 ; Vol. 50, No. 4. pp. 1263-1267.
@article{a92e724249534036894f9c8a5a9c0007,
title = "Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci",
abstract = "The activity of garenoxacin was compared to that of levofloxacin or penicillin in a rabbit model of Streptococcus mitis group (penicillin MIC, 0.125 μg/ml) and Streptococcus sanguinis group (penicillin MIC, 0.25 μg/ml) endocarditis. Garenoxacin and levofloxacin had MICs of 0.125 and 0.5 μg/ml, respectively, for both study isolates. Rabbits with catheter-induced aortic valve endocarditis were given no treatment, penicillin at 1.2 × 10 6 IU/8 h intramuscularly, garenoxacin at 20 mg/kg of body weight/12 h intravenously, or levofloxacin at 40 mg/kg/12 h intravenously. For both isolates tested, garenoxacin area under the curve (AUC)/MIC and maximum concentration of drug in serum (Cmax)/MIC ratios were 368 and 91, respectively. Rabbits were sacrificed after 3 days of treatment; cardiac valve vegetations were aseptically removed and quantitatively cultured. For S. mitis group experimental endocarditis, all studied antimicrobial agents were more active than no treatment (P < 0.001), whereas for S. sanguinis group endocarditis, no studied antimicrobial agents were more active than no treatment. We conclude that AUC/MIC and Cmax/MIC ratios may not predict activity of some quinolones in experimental viridans group endocarditis and that garenoxacin and levofloxacin may not be ideal choices for serious infections caused by some quinolone-susceptible viridans group streptococci.",
author = "Paloma Anguita-Alonso and Rouse, {Mark S.} and Piper, {Kerryl E.} and Steckelberg, {James M.} and Robin Patel",
year = "2006",
month = "4",
doi = "10.1128/AAC.50.4.1263-1267.2006",
language = "English (US)",
volume = "50",
pages = "1263--1267",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci

AU - Anguita-Alonso, Paloma

AU - Rouse, Mark S.

AU - Piper, Kerryl E.

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2006/4

Y1 - 2006/4

N2 - The activity of garenoxacin was compared to that of levofloxacin or penicillin in a rabbit model of Streptococcus mitis group (penicillin MIC, 0.125 μg/ml) and Streptococcus sanguinis group (penicillin MIC, 0.25 μg/ml) endocarditis. Garenoxacin and levofloxacin had MICs of 0.125 and 0.5 μg/ml, respectively, for both study isolates. Rabbits with catheter-induced aortic valve endocarditis were given no treatment, penicillin at 1.2 × 10 6 IU/8 h intramuscularly, garenoxacin at 20 mg/kg of body weight/12 h intravenously, or levofloxacin at 40 mg/kg/12 h intravenously. For both isolates tested, garenoxacin area under the curve (AUC)/MIC and maximum concentration of drug in serum (Cmax)/MIC ratios were 368 and 91, respectively. Rabbits were sacrificed after 3 days of treatment; cardiac valve vegetations were aseptically removed and quantitatively cultured. For S. mitis group experimental endocarditis, all studied antimicrobial agents were more active than no treatment (P < 0.001), whereas for S. sanguinis group endocarditis, no studied antimicrobial agents were more active than no treatment. We conclude that AUC/MIC and Cmax/MIC ratios may not predict activity of some quinolones in experimental viridans group endocarditis and that garenoxacin and levofloxacin may not be ideal choices for serious infections caused by some quinolone-susceptible viridans group streptococci.

AB - The activity of garenoxacin was compared to that of levofloxacin or penicillin in a rabbit model of Streptococcus mitis group (penicillin MIC, 0.125 μg/ml) and Streptococcus sanguinis group (penicillin MIC, 0.25 μg/ml) endocarditis. Garenoxacin and levofloxacin had MICs of 0.125 and 0.5 μg/ml, respectively, for both study isolates. Rabbits with catheter-induced aortic valve endocarditis were given no treatment, penicillin at 1.2 × 10 6 IU/8 h intramuscularly, garenoxacin at 20 mg/kg of body weight/12 h intravenously, or levofloxacin at 40 mg/kg/12 h intravenously. For both isolates tested, garenoxacin area under the curve (AUC)/MIC and maximum concentration of drug in serum (Cmax)/MIC ratios were 368 and 91, respectively. Rabbits were sacrificed after 3 days of treatment; cardiac valve vegetations were aseptically removed and quantitatively cultured. For S. mitis group experimental endocarditis, all studied antimicrobial agents were more active than no treatment (P < 0.001), whereas for S. sanguinis group endocarditis, no studied antimicrobial agents were more active than no treatment. We conclude that AUC/MIC and Cmax/MIC ratios may not predict activity of some quinolones in experimental viridans group endocarditis and that garenoxacin and levofloxacin may not be ideal choices for serious infections caused by some quinolone-susceptible viridans group streptococci.

UR - http://www.scopus.com/inward/record.url?scp=33645787255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645787255&partnerID=8YFLogxK

U2 - 10.1128/AAC.50.4.1263-1267.2006

DO - 10.1128/AAC.50.4.1263-1267.2006

M3 - Article

C2 - 16569838

AN - SCOPUS:33645787255

VL - 50

SP - 1263

EP - 1267

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -